A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Key facts
- Study ID
- NCT00063102
- Run by
- Abbott
- People needed
- 40
- Starts
- 2002-11-01
- Expected to finish
- 2004-08-01
- Last updated by the study team
- 2007-11-29
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Stage IIIB or IV breast cancer.
- Recurrent tumor after or while on taxane therapy (taxol or taxotere).
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney and liver function.
You may not qualify if…
- Pregnant or breast feeding.
- No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.
Where it is running
- Oncology-Hematology Group of South Florida — Miami, Florida, United States
- Clinical Research Network, Inc. — Plantation, Florida, United States
- Georgia Cancer Specialists — Atlanta, Georgia, United States
- Northwestern University Medical School Division of Hematology/Oncology — Chicago, Illinois, United States
- Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion — Indianapolis, Indiana, United States
- Northern Indiana Cancer Research Consortium — South Bend, Indiana, United States
- Oncology & Hemotology Associates of Kansas City, PA — Kansas City, Missouri, United States
- Texas Oncology — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.